Integra LifeSciences Holdings Corporation (IART) Shares Sold by Atlanta Capital Management Co. L L C

Atlanta Capital Management Co. L L C decreased its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 1.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 697,394 shares of the life sciences company’s stock after selling 13,297 shares during the quarter. Atlanta Capital Management Co. L L C owned approximately 0.89% of Integra LifeSciences Holdings Corporation worth $38,015,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Acrospire Investment Management LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 280.0% in the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares during the period. Riverhead Capital Management LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 49.9% in the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares during the period. LS Investment Advisors LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 4.6% in the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after purchasing an additional 111 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Integra LifeSciences Holdings Corporation by 223.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after purchasing an additional 1,751 shares during the period. Finally, San Francisco Sentry Investment Group CA acquired a new stake in shares of Integra LifeSciences Holdings Corporation in the second quarter valued at about $174,000. Institutional investors and hedge funds own 84.90% of the company’s stock.

Several analysts have recently issued reports on the stock. Oppenheimer Holdings, Inc. set a $60.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald assumed coverage on shares of Integra LifeSciences Holdings Corporation in a research report on Thursday, June 29th. They issued an “overweight” rating and a $65.00 target price on the stock. Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Raymond James Financial, Inc. lifted their target price on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, July 27th. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $53.00 target price (up previously from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, September 12th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Integra LifeSciences Holdings Corporation has a consensus rating of “Buy” and a consensus price target of $54.45.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://ledgergazette.com/2017/10/10/integra-lifesciences-holdings-corporation-iart-shares-sold-by-atlanta-capital-management-co-l-l-c.html.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up 0.14% during trading on Tuesday, hitting $49.50. 80,716 shares of the stock traded hands. The company’s 50 day moving average price is $50.68 and its 200-day moving average price is $49.30. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42. The stock has a market cap of $3.86 billion, a P/E ratio of 60.37 and a beta of 0.72.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.45. The firm had revenue of $282.16 million for the quarter, compared to analysts’ expectations of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm’s revenue was up 13.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.40 EPS. Equities research analysts forecast that Integra LifeSciences Holdings Corporation will post $1.91 earnings per share for the current fiscal year.

In other news, Director Barbara B. Hill purchased 5,050 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were bought at an average cost of $49.33 per share, with a total value of $249,116.50. Following the purchase, the director now directly owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald E. Morel, Jr. purchased 2,500 shares of the firm’s stock in a transaction on Thursday, August 3rd. The shares were purchased at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the completion of the purchase, the director now directly owns 29,612 shares in the company, valued at $1,459,575.48. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 17,550 shar

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Acrospire Investment Management LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 280.0% in the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares during the period. Riverhead Capital Management LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 49.9% in the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares during the period. LS Investment Advisors LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 4.6% in the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after purchasing an additional 111 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Integra LifeSciences Holdings Corporation by 223.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after purchasing an additional 1,751 shares during the period. Finally, San Francisco Sentry Investment Group CA acquired a new stake in shares of Integra LifeSciences Holdings Corporation in the second quarter valued at about $174,000. Institutional investors and hedge funds own 84.90% of the company’s stock.

Several analysts have recently issued reports on the stock. Oppenheimer Holdings, Inc. set a $60.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald assumed coverage on shares of Integra LifeSciences Holdings Corporation in a research report on Thursday, June 29th. They issued an “overweight” rating and a $65.00 target price on the stock. Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Raymond James Financial, Inc. lifted their target price on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, July 27th. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $53.00 target price (up previously from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, September 12th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Integra LifeSciences Holdings Corporation has a consensus rating of “Buy” and a consensus price target of $54.45.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://ledgergazette.com/2017/10/10/integra-lifesciences-holdings-corporation-iart-shares-sold-by-atlanta-capital-management-co-l-l-c.html.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up 0.14% during trading on Tuesday, hitting $49.50. 80,716 shares of the stock traded hands. The company’s 50 day moving average price is $50.68 and its 200-day moving average price is $49.30. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42. The stock has a market cap of $3.86 billion, a P/E ratio of 60.37 and a beta of 0.72.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.45. The firm had revenue of $282.16 million for the quarter, compared to analysts’ expectations of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm’s revenue was up 13.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.40 EPS. Equities research analysts forecast that Integra LifeSciences Holdings Corporation will post $1.91 earnings per share for the current fiscal year.

In other news, Director Barbara B. Hill purchased 5,050 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were bought at an average cost of $49.33 per share, with a total value of $249,116.50. Following the purchase, the director now directly owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald E. Morel, Jr. purchased 2,500 shares of the firm’s stock in a transaction on Thursday, August 3rd. The shares were purchased at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the completion of the purchase, the director now directly owns 29,612 shares in the company, valued at $1,459,575.48. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 17,550 shares of company stock worth $864,842. 21.50% of the stock is owned by corporate insiders.

Integra LifeSciences Holdings Corporation Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply